INCENTIVE STOCK OPTION AGREEMENTIncentive Stock Option Agreement • March 16th, 2016 • Phaserx, Inc. • Pharmaceutical preparations • Delaware
PHASERX, INC. SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT November 17, 2014Investors’ Rights Agreement • March 16th, 2016 • Phaserx, Inc. • Pharmaceutical preparations • Delaware
This Second Amended and Restated Investors’ Rights Agreement (this “Agreement”) is made as of November 17, 2014, by and among PhaseRx, Inc., a Delaware corporation (the “Company”), the persons and entities (each, a “Series A Investor”) listed on Exhibit A hereto, the persons and entities (each, a “Series A-1 Investor” and together with the Series A Investors, the “Investors”) listed on Exhibit A-1 hereto and the persons (each, a “Founder” and collectively, the “Founders”) listed on Exhibit B hereto. The Founders and Investors are referred to herein collectively as the “Stockholders.” Unless otherwise defined herein, capitalized terms used in this Agreement have the meanings ascribed to them in Section 1 hereof.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • March 16th, 2016 • Phaserx, Inc. • Pharmaceutical preparations
This Registration Rights Agreement (this “Agreement”) is made and entered into as of February 29, 2016, among PhaseRx, Inc., a Delaware corporation (the “Company”), and each of the several lenders signatory hereto (each such lender, a “Lender” and, collectively, the “Lenders”).
SIXTH AMENDMENT TO LEASELease Agreement • March 16th, 2016 • Phaserx, Inc. • Pharmaceutical preparations
THIS SIXTH AMENDMENT TO LEASE (this "Sixth Amendment") is made as of February 23, 2016, by and between ARE-SEATTLE NO. 10, LLC, a Delaware limited liability company ("Landlord"), and PHASERX INC., a Delaware corporation ("Tenant").
SUBORDINATION AGREEMENTSubordination Agreement • March 16th, 2016 • Phaserx, Inc. • Pharmaceutical preparations • New York
THIS SUBORDINATION AGREEMENT is entered into effective as of December 21, 2015, among the parties identified on Schedule A hereto (the “Subordinated Lender”), PhaseRx, Inc., a Delaware corporation (the “Borrower”), and Titan Multi-Strategy Fund I, LTD., in its capacity as a Senior Lender (as defined below) and in its capacity as representative for itself and for the other Senior Lenders (the “Representative”), the parties identified on Schedule B hereto (together with the Representative, are collectively referred to herein as the “Senior Lenders”).
